key: cord-0739941-l5lbt5oj
authors: Gautret, Philippe; Hoang, Van Thuan; Lagier, Jean-Christophe; Raoult, Didier
title: Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
date: 2021-01-04
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106237
sha: bbc8a431fc67eebb63d97a14cea5458c0aaa0af8
doc_id: 739941
cord_uid: l5lbt5oj

nan

We agree with colleagues that in our first paper, some estimate measures of effect modification such as relative risk reduction (RRR), absolute risk reduction (ARR) and number needed to treat (NNT) with the intervention of hydroxychloroquine were not analyzed [1] . In addition, excluding six patients from our analysis may have biased our results.

For that reason, we reanalyzed our data about all 42 patients initially enrolled in our survey. Outcome of analysis was "contagiousness at day 7". According to WHO criteria, patients were considered not contagious if they have two consecutive negative PCR results at least 24 hours apart [2] . Analysis was carried out using the STATA version 15.1 statistical package. Table 1 shows the contingency table and the estimated effect measures. The incidence of the hydroxychloroquine (HCQ) exposed group was 0.5 and the incidence of the unexposed group was 0.1667. The treatment with HCQ increased by a factor of 2 the proportion of non-contagious patients at day 7 (relative risk (RR) = 1. In conclusion, the reintegration of excluded patients in our analysis and the calculation of the estimate measures of effect modification confirm the effectiveness of the HCQ alone and of HCQ-AZ treatments on viral clearance of SARS-CoV-2 in COVID-19 patients.

https://doi.org/10.1016/j.ijantimicag.2020.106237 0924-8579/© 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

IJAA-D-20-00548 Parra-Lara LG. Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial

Guidance for discharge and ending isolation in the context of widespread community transmission of COVID-19 -first update

The authors declare no competing interests.

Not applicable